PROCEPT BioRobotics Corporation (BMV:PRCT)
Mexico · Delayed Price · Currency is MXN | Market Cap | 18.34B -69.6% |
| Revenue (ttm) | 5.81B +29.3% |
| Net Income | -1.85B |
| EPS | -33.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 948 |
| Open | 356.00 |
| Previous Close | n/a |
| Day's Range | 356.00 - 357.00 |
| 52-Week Range | 356.00 - 653.92 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hype... [Read more]
Financial Performance
In 2025, PROCEPT BioRobotics's revenue was $308.05 million, an increase of 37.22% compared to the previous year's $224.50 million. Losses were -$95.57 million, 4.55% more than in 2024.
Financial numbers in USD Financial StatementsNews
PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transfor...
Procept BioRobotics downgraded to Hold from Buy at Truist
Truist downgraded Procept BioRobotics (PRCT) to Hold from Buy with a price target of $25, down from $30, citing lowered confidence in the company’s procedure growth re-acceleration prospects. Procedur...
PROCEPT BioRobotics Slides: Conference presentation
PROCEPT BioRobotics has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Procept BioRobotics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar initiated coverage of Procept BioRobotics (PRCT) with an Outperform rating and $30 price target Over next 12 mon, a positive WATER IV trial will expand…
Leerink downgrades Procept BioRobotics to Market Perform, lowers target to $29
As previously reported, Leerink analyst Mike Kratky downgraded Procept BioRobotics (PRCT) to Market Perform from Outperform with a price target of $29, down from $31. With the stock approaching the…
Procept BioRobotics downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Procept BioRobotics (PRCT) to Market Perform from Outperform with a $29 price target
PROCEPT BioRobotics Transcript: 46th Annual William Blair Growth Stock Conference
Significant growth opportunities exist in the BPH and prostate cancer markets, with operational realignment and launch teams accelerating system adoption and utilization. Financial targets include EBITDA profitability by Q4, 65%+ gross margins, and robust revenue growth, supported by new clinical trials and product upgrades.
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the r...
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of...
PROCEPT BioRobotics Transcript: Bank of America Global Healthcare Conference 2026
Q1 revenue and margins exceeded expectations, with strong system placements and pricing. Commercial realignment and launch teams are driving growth, while patient education and targeted marketing aim to expand adoption. Margin expansion and positive EBITDA are on track, and the prostate cancer trial presents a significant future opportunity.
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solu...
Procept BioRobotics price target raised to $35 from $28 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Procept BioRobotics (PRCT) to $35 from $28 and keeps an Overweight rating on the shares. The firm notes the…
Procept BioRobotics price target raised to $28 from $27 at Baird
Baird raised the firm’s price target on Procept BioRobotics (PRCT) to $28 from $27 and keeps a Neutral rating on the shares. The firm updated its model following Q1 beat…
Procept BioRobotics affirms FY26 revenue $390M-$410M, consensus $395.9M
The company continues to expect full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period. The company continues to…
Procept BioRobotics reports Q1 EPS (56c), consensus (55c)
Reports Q1 revenue $83.1M, consensus $80.3M. The Company “recently received FDA clearance of its second-generation FirstAssist AI(TM) software, an advancement in personalized, image-guided planning fo...
PROCEPT BioRobotics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 20% year-over-year to $83.1 million, driven by strong U.S. and international performance, improved pricing, and operational realignment. Gross margin reached 65%, and full-year guidance was reiterated, with positive EBITDA expected in Q4.
PROCEPT BioRobotics Earnings release: Q1 2026
PROCEPT BioRobotics released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
PROCEPT BioRobotics Quarterly report: Q1 2026
PROCEPT BioRobotics has published its Q1 2026 quarterly earnings report on April 29, 2026.
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transf...
PROCEPT BioRobotics Proxy statement: Proxy filing
PROCEPT BioRobotics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
PROCEPT BioRobotics Proxy statement: Proxy filing
PROCEPT BioRobotics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transf...
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia Updated European Associati...
Procept BioRobotics announce international launch of HYDROS Robotic
Procept BioRobotics (PRCT) announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyper...
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platfor...